Skip to main content

Pfizer Spurs Pharma ETFs

Better-than-expected results from Pfizer spurs buying in pharma ETFs.



) -- Better-than-expected results from drug major


(PFE) - Get Pfizer Inc. Report

spurred buying in pharmaceutical and healthcare ETFs. Pfizer blew past estimates, helped by the acquisition of


and higher sales. The stock is up nearly 5% at $16.25.

Pharmaceutical HOLDRS

(PPH) - Get VanEck Pharmaceutical ETF Report

, which counts

Johnson & Johnson

(JNJ) - Get Johnson & Johnson Report

, Pfizer and


(MRK) - Get Merck & Co., Inc. Report

TheStreet Recommends

among its top holdings is rising 1.4% on Tuesday early trading. The

iShares Dow Jones US Healthcare

(IYH) - Get iShares U.S. Healthcare ETF Report


SPDR Health Care Sector

(XLV) - Get Health Care Select Sector SPDR Fund Report

are also heading higher.

Weak economic data appears to be driving buyers to safe havens like gold. The


(GLD) - Get SPDR Gold Shares Report

is up 0.6% to $116.30. Gold mining companies, a riskier way to invest in gold, is also seeing buying interest. The

Market Vectors Junior Gold Miners ETF

(GDXJ) - Get VanEck Junior Gold Miners ETF Report

is gaining 2.3%.

A blowout quarter from



and reports that a South Korean company is going to acquire a 49.9% stake in the Chinese solar module maker, is boosting buying in solar ETFs. The

Market Vectors Solar ETF


is up 1.6% in Tuesday early trading, while

Claymore/MAC Solar Energy ETF

(TAN) - Get Invesco Solar ETF Report

is up 1.1%.

-- Reported by Shanthi Venkataraman in New York.

Follow on


and become a fan on


Copyright 2010 Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.